Target intelligence / Profile preview

Glutamine amidotransferase class 1 domain containing 1 (GATD1)

Target
GATD1
Molecular classification
Enzyme (predicted glyoxalase III activity), Peptidase C56 family, Endosomal Rab5 effector complex (FERRY complex subunit)
01

Overview

Glutamine amidotransferase class 1 domain containing 1 (GATD1) is a protein-coding gene and a member of the peptidase C56 family. It is a component of the FERRY complex, a five-subunit endosomal Rab5 and RNA/ribosome intermediary complex, which interacts directly with mRNAs and RAB5A. This protein is involved in facilitating the localization and distribution of specific mRNAs, most likely by mediating their endosomal transport. GATD1 is predicted to possess glyoxalase III activity, catalyzing methylglyoxal metabolism to D-lactate via S-lactoyl-glutathione, and appears to function in cellular mRNA and ribosome recruitment to early endosomes through direct mRNA interaction. There are no current reports of direct disease association, therapeutic targeting, or pharmacological modulation of GATD1 in the literature[4][1].

Other names
Glutamine amidotransferase-like class 1 domain-containing protein 1GATD1FERRY5PDDC1Fy-5FLJ34283Ferry endosomal RAB5 effector complex subunit 5Parkinson disease 7 domain-containing protein 1
02

Mechanism of action

Not applicable; no drugs known to target this molecule

03

Biological functions

Predicted glyoxalase III activityInvolved in methylglyoxal catabolic process to D-lactate via S-lactoyl-glutathioneMediates localization and distribution of specific mRNAs, likely by endosomal transport as part of the FERRY complexRecruits mRNAs and ribosomes to early endosomes through direct mRNA interaction
04

Disease associations

Other (no direct or well-established links to major diseases based on available data; contextually related proteins have roles in Parkinson's disease, but this protein has no specific known disease linkage)No evidence for roles in cancer, inflammation, neurodegeneration, infection, or cardiovascular disease
05

Safety considerations

None documented
06

Interacting drugs

None reported
07

Biomarkers

None known or documented

Beyond the preview

Go deeper on Glutamine amidotransferase class 1 domain containing 1 (GATD1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamine amidotransferase class 1 domain containing 1 (GATD1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call